Analysts said Eli Lilly and Co. shares could climb to $2,000 per share based on the company's pharmaceutical growth [4, 5].
This potential surge would position the U.S. company to become a $2 trillion market-cap health-care stock. Such a valuation would reflect the massive commercial demand for metabolic health treatments, and the company's expanding portfolio of weight-loss medications.
The optimism is driven by the strong performance of diabetes and obesity drugs, including Mounjaro and tirzepatide [6]. Further fueling this growth was the launch of Foundayo, a new weight-loss pill, in April 2026 [7].
Recent data shows the stock closed at $1,006.70 as of May 14 [1]. The company's market capitalization currently stands at $920 billion [2]. This represents a decline from last year, when the company reached a $1 trillion market cap [3].
Despite the current valuation, some analysts said the $2,000 target is achievable [4, 5]. Other reports said the stock has not performed as well since it first hit the trillion-dollar milestone [3]. The disparity in outlook highlights the volatility associated with high-growth pharmaceutical stocks.
Eli Lilly continues to leverage its position in the obesity market to drive revenue. The company's ability to scale production and maintain the efficacy of its drug pipeline remains central to these price projections.
“Eli Lilly shares could climb to $2,000 per share”
The projection reflects a broader market trend where GLP-1 agonists and related weight-loss treatments are transforming pharmaceutical valuations. If Eli Lilly reaches a $2 trillion market cap, it would signal that the market views obesity treatment not as a niche category, but as a primary driver of global healthcare spending and corporate value for the next decade.
